Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma / Massari, Francesco; Ciccarese, Chiara; Santoni, Matteo; Lopez Beltran, Antonio; Scarpelli, Marina; Montironi, Rodolfo; Cheng, Liang. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - STAMPA. - 15:12(2015), pp. 1367-1369. [10.1586/14737140.2015.1110488]
Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma
SANTONI, MATTEO;SCARPELLI, Marina;MONTIRONI, RODOLFO;
2015-01-01
Abstract
Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
